Abstract
Aim
To investigate whether omitting intra-operative staging of the sentinel lymph node
(SLN) in T1-N0 breast-cancer patients is feasible and convenient because it could
allow a more efficient management of human and logistic resources without leading
to an unacceptable increase in the rate of delayed axillary lymph node dissection
(ALND).
Methods
According to the experimental procedure, T1a–T1b-patients were to not receive any
intra-operative SLN evaluation on frozen sections (FS). In all T1c-patients, the SLN
was macroscopically examined; if the node appeared clearly free of disease, no further
intra-operative assessment was performed; if the node was clearly metastatic or presented
a dubious aspect, the pathologist proceeded with analysis on FS. T2-patients, enrolled
in the study as reference group, were treated according to the institutional standard
procedure; they all received SLN staging on FS.
Results
The study included 395 T1-N0-patients. Among the 118 T1a–T1b-patients whose SLN was
not analyzed at surgery, 12 (10.2%) were recalled for ALND. In the group of 258 T1c-patients,
112 received SLN analysis on FS and 146 did not. An SLN falsely negative either at
macroscopic or FS examination was found in 33 (12.8%) cases. Overall, the rate of
recall for ALND was 11.6% as compared to 8.4% in T2-patients. Using the experimental
protocol, the institution reached a 9.6% cost saving, as compared to the standard
procedure.
Conclusions
Omission of SLN intra-operative staging in T1-N0-patients is rather safe. It provides
the institution with both management and economical advantages.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis.Cancer. 2006; 106: 4-16
- National surgical adjuvant breast and bowel project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.Lancet Oncol. 2007; 8: 881-888
- Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial.J Natl Cancer Inst. 2006; 98: 599-609
- Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.Lancet. 1997; 349: 1864-1867
- Sentinel lymphadenectomy in breast cancer.J Clin Oncol. 1997; 15: 2345-2350
- The sentinel node in breast cancer-a multicenter validation study.N Engl J Med. 1998; 339: 941-946
- Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania.Cancer. 2002; 94: 2542-2551
- American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.J Clin Oncol. 2005; 23: 7703-7720
- Image-detected breast cancer: state of the art diagnosis and treatment.J Am Coll Surg. 2005; 201: 586-597
- Is routine intraoperative frozen-section examination of sentinel lymph nodes in breast cancer worthwhile?.Ann Surg Oncol. 2000; 7: 651-655
- Does the benefit of sentinel node frozen section vary between patients with invasive duct, invasive lobular, and favorable histologic subtypes of breast cancer?.Ann Surg. 2008; 247: 143-149
- Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial.Ann Oncol. 2009; 20: 1001-1007
Article info
Publication history
Accepted:
June 7,
2010
Identification
Copyright
© 2010 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.